As if a slowing economy and dwindling product pipelines weren’t enough to contend with, drug companies are under mounting pressure to face a regulatory issue that many compare to the “Y2K bug” of the late 1990s: compliance with the FDA’s 21 CFR Part 11 regulation. The ruling, which governs the security of electronic records submitted to the agency, has been in place since 1997, but the FDA is only just beginning to crack down on companies who fail to meet the minimum validation requirements (see sidebar, p. 9).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.